Related Experiment Video
Updated: Apr 30, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical
S Z Xie1,2, J E Salem3, A Nagrial2,4
1Department of Clinical Immunology and Immunopathology, ICPMR, Westmead Hospital, Sydney, New South Wales, Australia.
Abstract:
Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple "M" syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%-2% of patients receiving ICI, with an associated mortality of up to 50%. Based on international evidence and local experience, we have developed a clinical pathway in our institution as a guide to the early identification and targeted management of this condition.
More Related Videos
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
Related Concept Videos
Myocarditis III: Medical Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management
Myocarditis IV: Nursing Management
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy II: Dilated Cardiomyopathy